SYK Stock Recent News

The Investment Committee kick off the week with their top picks. Don't miss it!

Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

SYK's first-quarter results reflect strong segmental performance, along with a rise in operating margin.

Stryker Corporation (NYSE:SYK ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Jason Beach - Vice President, Finance and Investor Relations Preston Wells - Vice President, Chief Financial Officer Conference Call Participants Marcus Robert - JPMorgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Ryan Zimmerman - BTIG Travis Steed - Bank of America Vijay Kumar - Evercore ISI David Roman - Goldman Sachs Philip Chickering - Deutsche Bank Matthew Miksic - Barclays Patrick Wood - Morgan Stanley Shagun Singh - RBC Mike Matson - Needham & Company Caitlin Cronin - Canaccord Genuity Danielle Antalffy - UBS Matt Taylor - Jefferies Operator Welcome to the First Quarter 2025 Stryker Earnings Call. My name is Luke and I'll be your operator for today's call.

Stryker beat Wall Street estimates for quarterly profit on Thursday, fueled by strong demand for its medical and surgical devices.

Stryker (SYK) came out with quarterly earnings of $2.84 per share, beating the Zacks Consensus Estimate of $2.73 per share. This compares to earnings of $2.50 per share a year ago.

Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billion Organic net sales increased 10.1% Reported operating income margin of 14.3% Adjusted operating income margin (1) increased 100 bps to 22.9% Reported EPS decreased 17.6% to $1.69 Adjusted EPS (1) increased 13.6% to $2.84   First Quarter Net Sales Growth Overview   Reported   Foreign Currency Exchange   Constant Currency   Acquisitions / Divestitures   Organic MedSurg and Neurotechnology         13.4         %           (0.8)        %           14.2         %           3.5         %           10.7         % Orthopaedics         9.7                     (1.0)                     10.7                     1.4                     

This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.

SYK's first-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?